DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
AGS-16C3F
2
Unknown
Investigational
Unknown
Unknown
Carcinoma, Renal Cell
Ectonucleotide pyrophosphatase/phosphodiesterase family member 3 binding agent
AGS-16C3F
×
Maximum Phase:
2
First Approval:
None
UNII:
VC1D38AGN9
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MM-111
2
Unknown
Investigational
Unknown
Unknown
Breast Neoplasms
ErbB-2/ErbB-3 heterodimer inhibitor
MM-111
×
Maximum Phase:
2
First Approval:
None
UNII:
6IJ4CQY76O
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
USISTAPIDE
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2; Obesity
Unknown
USISTAPIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
73YSY3U094
Molecule Type:
Small molecule
Molecular Formula:
C34H31F3N2O3
Molecular Weight:
572.63
AlogP:
7.72
PSA:
58.64
HBD:
1.0
HBA:
#RotB:
7.0
Source:
OLEIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Glioma; Multiple Sclerosis; Adenoma
Unknown
OLEIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
2UMI9U37CP
Molecule Type:
Small molecule
Molecular Formula:
C18H34O2
Molecular Weight:
282.47
AlogP:
6.11
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
15.0
Source:
RITANSERIN
2
Small molecule
Investigational
Unknown
Unknown
Cocaine-Related Disorders
Unknown
RITANSERIN
×
Maximum Phase:
2
First Approval:
None
UNII:
145TFV465S
Molecule Type:
Small molecule
Molecular Formula:
C27H25F2N3OS
Molecular Weight:
477.58
AlogP:
5.48
PSA:
37.61
HBD:
0.0
HBA:
#RotB:
5.0
Source:
CHF6001
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
CHF6001
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TD-139
2
Small molecule
Investigational
Unknown
Unknown
Idiopathic Pulmonary Fibrosis; Severe Acute Respiratory Syndrome
Galectin-3 inhibitor
TD-139
×
Maximum Phase:
2
First Approval:
None
UNII:
60Y0GUO72B
Molecule Type:
Small molecule
Molecular Formula:
C28H30F2N6O8S
Molecular Weight:
648.65
AlogP:
-0.12
PSA:
201.26
HBD:
6.0
HBA:
#RotB:
8.0
Source:
ETHION
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ETHION
×
Maximum Phase:
2
First Approval:
None
UNII:
2TI07NO12Y
Molecule Type:
Small molecule
Molecular Formula:
C9H22O4P2S4
Molecular Weight:
384.49
AlogP:
5.01
PSA:
36.92
HBD:
0.0
HBA:
#RotB:
12.0
Source:
TESNATILIMAB
2
Antibody
Investigational
Unknown
Unknown
Alopecia Areata; Crohn Disease
Unknown
TESNATILIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
2B860WP9F0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROMYELOCEL-L
2
Cell
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Unknown
ROMYELOCEL-L
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ETAVOPIVAT
2
Small molecule
Investigational
Unknown
Unknown
Anemia, Sickle Cell
Unknown
ETAVOPIVAT
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C22H23N3O6S
Molecular Weight:
457.51
AlogP:
0.77
PSA:
109.27
HBD:
1.0
HBA:
#RotB:
5.0
Source:
TEGOBUVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitor
TEGOBUVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
5NOK5X389M
Molecule Type:
Small molecule
Molecular Formula:
C25H14F7N5
Molecular Weight:
517.41
AlogP:
6.73
PSA:
56.49
HBD:
0.0
HBA:
#RotB:
4.0
Source:
CENERSEN
2
Oligonucleotide
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute
p53 mRNA antisense inhibitor
CENERSEN
×
Maximum Phase:
2
First Approval:
None
UNII:
K6KJ8AZ05F
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
METELIMUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Transforming growth factor beta-1 inhibitor
METELIMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
4AR6718OL0
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ABT-510
2
Protein
Investigational
Unknown
Unknown
Brain Neoplasms; Head and Neck Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Hodgkin Disease; Lymphoma, Non-Hodgkin; Melanoma; Sarcoma
Unknown
ABT-510
×
Maximum Phase:
2
First Approval:
None
UNII:
CRR8E37XOB
Molecule Type:
Protein
Molecular Formula:
C46H83N13O11
Molecular Weight:
994.25
AlogP:
-2.4
PSA:
358.05
HBD:
11.0
HBA:
#RotB:
30.0
Source:
BAVISANT
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Attention Deficit Disorder with Hyperactivity
Histamine H3 receptor antagonist
BAVISANT
×
Maximum Phase:
2
First Approval:
None
UNII:
9827P7LFVH
Molecule Type:
Small molecule
Molecular Formula:
C19H27N3O2
Molecular Weight:
329.44
AlogP:
1.44
PSA:
36.02
HBD:
0.0
HBA:
#RotB:
4.0
Source:
(+)-SECOISOLARICIRESINOL
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
(+)-SECOISOLARICIRESINOL
×
Maximum Phase:
2
First Approval:
None
UNII:
M8QRJ7JEJH
Molecule Type:
Small molecule
Molecular Formula:
C20H26O6
Molecular Weight:
362.42
AlogP:
2.12
PSA:
99.38
HBD:
4.0
HBA:
#RotB:
9.0
Source:
BRADANICLINE
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity; Cough; Schizophrenia
Neuronal acetylcholine receptor protein alpha-7 subunit agonist
BRADANICLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
UM3821998K
Molecule Type:
Small molecule
Molecular Formula:
C22H23N3O2
Molecular Weight:
361.45
AlogP:
3.26
PSA:
58.37
HBD:
1.0
HBA:
#RotB:
4.0
Source:
CREATININE
2
Small molecule
Investigational
Unknown
Unknown
Amyotrophic Lateral Sclerosis
Unknown
CREATININE
×
Maximum Phase:
2
First Approval:
None
UNII:
AYI8EX34EU
Molecule Type:
Small molecule
Molecular Formula:
C4H7N3O
Molecular Weight:
113.12
AlogP:
-1.23
PSA:
58.69
HBD:
1.0
HBA:
#RotB:
0.0
Source:
ZAPNOMETINIB
2
Unknown
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
ZAPNOMETINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLYCIDIDAZOLE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GLYCIDIDAZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C18H23N7O10
Molecular Weight:
497.42
AlogP:
-0.31
PSA:
215.06
HBD:
1.0
HBA:
#RotB:
14.0
Source:
AZD5672
2
Small molecule
Investigational
Unknown
Unknown
Kidney Diseases; Arthritis, Rheumatoid
C-C chemokine receptor type 5 antagonist
AZD5672
×
Maximum Phase:
2
First Approval:
None
UNII:
61XQN688TW
Molecule Type:
Small molecule
Molecular Formula:
C31H43F2N3O5S2
Molecular Weight:
639.83
AlogP:
4.07
PSA:
95.07
HBD:
0.0
HBA:
#RotB:
11.0
Source:
OC000459
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Rhinitis, Allergic, Seasonal
G protein-coupled receptor 44 antagonist
OC000459
×
Maximum Phase:
2
First Approval:
None
UNII:
04XB9TB8OL
Molecule Type:
Small molecule
Molecular Formula:
C21H17FN2O2
Molecular Weight:
348.38
AlogP:
4.31
PSA:
55.12
HBD:
1.0
HBA:
#RotB:
4.0
Source:
SITAMAQUINE
2
Small molecule
Investigational
Unknown
Unknown
Leishmaniasis
Unknown
SITAMAQUINE
×
Maximum Phase:
2
First Approval:
None
UNII:
5AIJ4TGC6B
Molecule Type:
Small molecule
Molecular Formula:
C21H33N3O
Molecular Weight:
343.52
AlogP:
4.87
PSA:
37.39
HBD:
1.0
HBA:
#RotB:
11.0
Source:
AMELPARIB DIHYDROCHLORIDE DIHYDRATE
2
Unknown
Investigational
Unknown
Unknown
Stroke; Ischemic Stroke
Unknown
AMELPARIB DIHYDROCHLORIDE DIHYDRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
H15GT9J2LB
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUFUGOLIX
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Gonadotropin-releasing hormone receptor antagonist
SUFUGOLIX
×
Maximum Phase:
2
First Approval:
None
UNII:
56S17Z6X9M
Molecule Type:
Small molecule
Molecular Formula:
C36H31F2N5O4S
Molecular Weight:
667.74
AlogP:
6.52
PSA:
97.6
HBD:
2.0
HBA:
#RotB:
10.0
Source:
PIRITREXIM
2
Small molecule
Investigational
Unknown
Unknown
Urethral Neoplasms; Urinary Bladder Neoplasms
Dihydrofolate reductase inhibitor
PIRITREXIM
×
Maximum Phase:
2
First Approval:
None
UNII:
MK2A783ZUT
Molecule Type:
Small molecule
Molecular Formula:
C17H19N5O2
Molecular Weight:
325.37
AlogP:
2.11
PSA:
109.17
HBD:
2.0
HBA:
#RotB:
4.0
Source:
TIPEPIDINE
2
Small molecule
Investigational
Unknown
Unknown
Attention Deficit Disorder with Hyperactivity; Cough; Depressive Disorder
Unknown
TIPEPIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
2260ZP67IT
Molecule Type:
Small molecule
Molecular Formula:
C15H17NS2
Molecular Weight:
275.44
AlogP:
4.34
PSA:
3.24
HBD:
0.0
HBA:
#RotB:
2.0
Source:
FLORBENAZINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FLORBENAZINE
×
Maximum Phase:
2
First Approval:
None
UNII:
K5GDY88W5X
Molecule Type:
Small molecule
Molecular Formula:
C21H32FNO3
Molecular Weight:
365.49
AlogP:
3.76
PSA:
41.93
HBD:
1.0
HBA:
#RotB:
7.0
Source:
CDP-860
2
Antibody
Investigational
Unknown
Unknown
Unknown
Platelet-derived growth factor receptor beta inhibitor
CDP-860
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOMUZOTUXIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
TOMUZOTUXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
5P637IXG16
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DUSIGITUMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Neoplasms; Breast Neoplasms
Insulin-like growth factor II inhibitor
DUSIGITUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0Z70DT5PRX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KETOPROFEN SODIUM
2
Small molecule
Investigational
Unknown
Unknown
Muscular Diseases
Unknown
KETOPROFEN SODIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
5R10M39KS7
Molecule Type:
Small molecule
Molecular Formula:
C16H13NaO3
Molecular Weight:
276.27
AlogP:
3.11
PSA:
54.37
HBD:
1.0
HBA:
#RotB:
4.0
Source:
APOLIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma
Human leukocyte antigen DR beta chain inhibitor
APOLIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
G88KCP51RE
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ME-401
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ME-401
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
127
128
129
130
131
132
133
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA